C-17 Hydroxylase Deficiency
- Author: Gabriel I Uwaifo, MD; Chief Editor: George T Griffing, MD more...
The rare variant of congenital adrenal hyperplasia (CAH) known as 17-hydroxylase deficiency was first described in the 1960s in patients with sexual infantilism and hypertension. It has also been described to present in the setting of male pseudohermaphroditism.[1, 2] Patients with 17-hydroxylase deficiency have alterations in their CYP17 gene, which encodes the P450C17 enzyme.[3, 4, 5, 6] This enzyme plays a central role in steroidogenesis. See the image below. Steroidogenesis is essential for the production of cortisol and sex steroids. Thus, patients with 17-hydroxylase deficiency have reduced secretion of cortisol, androgen, and estrogen, with adrenal and gonadal steroidogenesis impairment. Although patients with 17-hydroxylase deficiency have decreased cortisol production, they do not have signs or symptoms of adrenal insufficiency due to elevations of corticosterone and glucocorticoids.
See the image below.
CAH due to 17-hydroxylase deficiency is associated with hypertension and an excess of deoxycorticosterone (DOC), which is the second most common naturally occurring mineralocorticoid after aldosterone. DOC excess typically is associated with hypertension, hypokalemia, and renin and aldosterone suppression. Among the conditions associated with DOC excess are Cushing syndrome (particularly the ectopic adrenocorticotropic hormone [ACTH] variants and in the setting of adrenocortical carcinomas), adrenal tumors, CAH due to 11-hydroxylase deficiency, and primary cortisol resistance.[7, 8]
In the zona fasciculata, the typical end-product of the steroid biosynthetic pathway is cortisol, as shown in the image below, which regulates pituitary ACTH production through negative feedback inhibition. Loss of 17-hydroxylase activity in the adrenal gland blocks the synthesis of cortisol and results in an increase in ACTH production. See the image below.
Aldosterone is the main mineralocorticoid produced by the adrenal zona glomerulosa, and its production is regulated by the renin-angiotensin system. A 17-hydroxy pathway similar to the active pathway in the zona glomerulosa occurs in the zona fasciculata; however, the final product is corticosterone rather than aldosterone. In the glomerulosa, but not in the fasciculata, corticosterone is hydroxylated and oxidized at the 18 position to produce aldosterone. The adrenal fasciculata's production of corticosterone, a weak glucocorticoid, and DOC, a potent mineralocorticoid, is minimal and relatively unimportant in healthy, normal individuals, but it is important in patients with 17-hydroxylase deficiency.
Patients with 17-hydroxylase deficiency do not manifest symptoms of adrenal insufficiency because of increased production of corticosterone, a glucocorticoid. Because corticosterone is a weaker glucocorticoid than cortisol, very high levels of corticosterone are necessary before feedback inhibition on pituitary ACTH production occurs. As a result, a new steady state is established, with dramatically elevated levels of steroid intermediates, such as progesterone, DOC, and corticosterone.
As the biosynthetic pathway diagram above shows, 17-hydroxylase is not required for aldosterone synthesis. However, the elevated DOC levels from the zona fasciculata result in salt retention, volume expansion, hypertension, hypokalemia, and down-regulation of the renin-angiotensin axis. This secondarily inhibits aldosterone production, which typically is virtually absent in affected patients.
The persistently elevated ACTH levels continue to drive overproduction of the preceding precursors, especially progesterone, DOC, and corticosterone. In these patients, DOC is principally under the control of ACTH rather than angiotensin, and it is predominantly secreted by the zona fasciculata rather than by the glomerulosa. DOC is metabolized in the liver to tetrahydrodeoxycorticosterone, which is then conjugated to glucuronic acid and excreted in the urine. DOC can be further hydroxylated to 19-nordeoxycorticosterone, which also is a potent mineralocorticoid. Thus, 19-Nor-deoxycorticosterone levels also are elevated in patients with this syndrome.
In all variants of 17-hydroxylase deficiency, the production of sex steroids is absent, resulting in a compensatory increase in levels of follicle-stimulating hormone and luteinizing hormone comparable to that in menopause. In humans, the gene product for 17-alpha hydroxylase (P450C17) is expressed in the adrenal cortex, testes, and ovaries but not in the placenta. The adrenals produce glucocorticoids, mineralocorticoids, and C-19 steroids. The gonads, on the other hand, predominantly produce the C-19 steroids and sex hormones. Thus, in patients with 17-hydroxylase deficiency, adrenal and gonadal steroidogenesis are impaired.
P450C17 performs multiple biochemical transformations. It 17-hydroxylates pregnenolone and progesterone and also is responsible for 17,20-lyase activity. Lin and colleagues described the differential regulation of the 2 principal activities of P450C17. Also, Zhang and associates described the developmentally regulated expression of P450C17. They suggested that P450C17 may play an important role in adrenarche, an event in children that is characterized by a dramatic rise in adrenal dehydroepiandrosterone (DHEA) production.
Patients with 17-hydroxylase deficiency typically have impairments of 17-alpha-hydroxylase and 17,20-lyase activity. However, cases of isolated 17,20-lyase deficiency have been described, with CYP17 gene mutations for such cases having been confirmed by molecular genetic studies. Cases of isolated 17-alpha-hydroxylase deficiency have also been described.
The occurrence of 17-hydroxylase deficiency reportedly is very rare. It is responsible for less than 1% of all cases of congenital adrenal hyperplasia. At least 14 cases of isolated 17,20 lyase deficiency have been reported in the presence of normal 17-alpha-hydroxylase activity.
A deficiency of 21-hydroxylase is by far the most common variant of CAH (95% of all cases), but the exact prevalence of 17-hydroxylase deficiency is unknown. Most authorities indicate that it is rare and is certainly less common than 11-beta-hydroxylase deficiency. More than 120 cases of C-17 hydroxylase deficiency have been reported in the world medical literature. Prevalence may be more common in Brazil, where there appears to be a founder effect, with more than 80% of the gene mutations identified being due to 2 specific mutations. In Japan, several cases of 17-alpha hydroxylase deficiency associated with elevated aldosterone levels have been reported. The exact pathophysiologic mechanism for this enigmatic situation is unclear.
Mortality and major morbidities associated with 17-hydroxylase deficiency stem mainly from delayed recognition or nonrecognition of hypertension.
The long-term sequelae of myocardial infarction, cerebrovascular accident, renal failure, heart failure, and peripheral vascular disease may occur if blood pressure is not well controlled.
The psychologic impact of the hypogonadism and/or ambiguous genitalia associated with the condition may impact the quality of life and social adjustment of patients with 17-hydroxylase deficiency.
Fewer than 150 well-validated cases of 17-hydroxylase deficiency have been documented in the medical literature; therefore, making any definitive statement as to the relative frequency of this condition among the major ethnic groups is difficult.
Cases from all over the world have been described, but a relatively low rate of this syndrome and of congenital adrenal hyperplasia in general appears among blacks from Africa and from the black diaspora.
Because 17-hydroxylase deficiency is an autosomal recessive disease, males and females are affected equally.
It is important to note is that if karyotypes are not checked, the disease will be detected more often in females than in males, because males with classic 17-hydroxylase deficiency are phenotypic females.
The most common stage of life at which 17-hydroxylase deficiency is detected is late adolescence, when the lack of sexual development associated with the syndrome becomes evident. Patients also may present with hypertension and hypokalemia.
Zachmann M, Vollmin JA, Hamilton W, et al. Steroid 17,20-desmolase deficiency: a new cause of male pseudohermaphroditism. Clin Endocrinol (Oxf). 1972 Oct. 1(4):369-85. [Medline].
Zachmann M, Werder EA, Prader A. Two types of male pseudohermaphroditism due to 17, 20-desmolase deficiency. J Clin Endocrinol Metab. 1982 Sep. 55(3):487-90. [Medline].
Arlt W, Walker EA, Draper N, et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet. 2004 Jun 26. 363(9427):2128-35. [Medline].
Auchus RJ. The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am. 2001 Mar. 30(1):101-19, vii. [Medline].
Winter JS, Couch RM, Muller J. Combined 17-hydroxylase and 17,20-desmolase deficiencies: evidence for synthesis of a defective cytochrome P450c17. J Clin Endocrinol Metab. 1989 Feb. 68(2):309-16. [Medline].
Bhangoo A, Aisenberg J, Chartoffe A, et al. Novel mutation in cytochrome P450c17 causes complete combined 17alpha-hydroxylase/17,20-lyase deficiency. J Pediatr Endocrinol Metab. 2008 Feb. 21(2):185-90. [Medline].
Falhammar H, Filipsson Nystrom H, Ekstrom U, Granberg S, Wedell A, Thoren M. Fertility, Sexuality and Testicular Adrenal Rest Tumors in Adult Males with Congenital Adrenal Hyperplasia. Eur J Endocrinol. 2011 Dec 9. [Medline].
Smeets EE, Span PN, van Herwaarden AE, Wevers RA, Hermus AR, Sweep FC, et al. Molecular Characterization of Testicular Adrenal Rest Tumors in Congenital Adrenal Hyperplasia; Lesions with both Adrenocortical and Leydig Cell Features. J Clin Endocrinol Metab. 2014 Dec 8. jc20142036. [Medline].
Shackleton CH, Neres MS, Hughes BA, et al. 17-hydroxylase/C17,20-lyase (CYP17) is not the enzyme responsible for side-chain cleavage of cortisol and its metabolites. Steroids. 2008 Jul. 73(6):652-6. [Medline].
Sarafoglou K, Zimmerman CL, Gonzalez-Bolanos MT, Willis BA, Brundage R. Interrelationships Among Cortisol, 17-Hydroxyprogesterone, and Androstenendione Exposures in the Management of Children With Congenital Adrenal Hyperplasia. J Investig Med. 2014 Nov 10. [Medline].
Lin D, Black SM, Nagahama Y. Steroid 17 alpha-hydroxylase and 17,20-lyase activities of P450c17: contributions of serine106 and P450 reductase. Endocrinology. 1993 Jun. 132(6):2498-506. [Medline]. [Full Text].
Zhang LH, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci U S A. 1995 Nov 7. 92(23):10619-23. [Medline]. [Full Text].
Geller DH, Auchus RJ, Mendonca BB. The genetic and functional basis of isolated 17,20-lyase deficiency. Nat Genet. 1997 Oct. 17(2):201-5. [Medline].
Belgini DR, Mello MP, Baptista MT, Oliveira DM, Denardi FC, Garmes HM, et al. Six new cases confirm the clinical molecular profile of complete combined 17a-hydroxylase/ 17,20-lyase deficiency in Brazil. Arq Bras Endocrinol Metabol. 2010 Nov. 54(8):711-6. [Medline].
Benetti-Pinto CL, Vale D, Garmes H, et al. 17-hydroxyprogesterone deficiency as a cause of sexual infantilism and arterial hypertension: laboratory and molecular diagnosis--a case report. Gynecol Endocrinol. 2007 Feb. 23(2):94-8. [Medline].
Moran C, Knochenhauer ES, Azziz R. Non-classic adrenal hyperplasia in hyperandrogenism: a reappraisal. J Endocrinol Invest. 1998 Nov. 21(10):707-20. [Medline].
Won GS, Chiu CY, Tso YC, et al. A compound heterozygous mutation in the CYP17 (17alpha-hydroxylase/17,20-lyase) gene in a Chinese subject with congenital adrenal hyperplasia. Metabolism. 2007 Apr. 56(4):504-7. [Medline].
Wit JM, van Roermund HP, Oostdijk W. Heterozygotes for 17 alpha-hydroxylase deficiency can be detected with a short ACTH test. Clin Endocrinol (Oxf). 1988 Jun. 28(6):657-64. [Medline].
Teixeira SR, Elias PC, Andrade MT, Melo AF, Elias Junior J. The role of imaging in congenital adrenal hyperplasia. Arq Bras Endocrinol Metabol. 2014 Oct. 58(7):701-8. [Medline].
German A, Suraiya S, Tenenbaum-Rakover Y, et al. Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. J Clin Endocrinol Metab. 2008 Dec. 93(12):4707-10. [Medline].
Moreira RP, Jorge AA, Gomes LG, Kaupert LC, Massud Filho J, Mendonca BB, et al. Pharmacogenetics of glucocorticoid replacement could optimize the treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clinics (Sao Paulo). 2011. 66(8):1361-6. [Medline]. [Full Text].
Carlson AD, Obeid JS, Kanellopoulou N. Congenital adrenal hyperplasia: update on prenatal diagnosis and treatment. J Steroid Biochem Mol Biol. 1999 Apr-Jun. 69(1-6):19-29. [Medline].
Callies F, Fassnacht M, van Vlijmen JC. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab. 2001 May. 86(5):1968-72. [Medline]. [Full Text].
Bee YM, Manju C, Papari-Zareei M, Auchus RJ. Phenotypic variation in a Chinese family with 46,XY and 46,XX 17?-hydroxylase deficiency. Gynecol Endocrinol. 2011 Nov 16. [Medline].
Biglieri EG, Kater CE. 17 alpha-hydroxylation deficiency. Endocrinol Metab Clin North Am. 1991 Jun. 20(2):257-68. [Medline].
Costa-Santos M, Kater CE, Auchus RJ. Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. J Clin Endocrinol Metab. 2004 Jan. 89(1):49-60. [Medline]. [Full Text].
Fluck CE, Tajima T, Pandey AV, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet. 2004 Mar. 36(3):228-30. [Medline].
Kater CE, Biglieri EG. Disorders of steroid 17 alpha-hydroxylase deficiency. Endocrinol Metab Clin North Am. 1994 Jun. 23(2):341-57. [Medline].
Mantero F, Opocher G, Rocco S. Long-term treatment of mineralocorticoid excess syndromes. Steroids. 1995 Jan. 60(1):81-6. [Medline].
Miller WL. Early steps in androgen biosynthesis: from cholesterol to DHEA. Baillieres Clin Endocrinol Metab. 1998 Apr. 12(1):67-81. [Medline].
New MI, Newfield RS. Congenital adrenal hyperplasia. Bardin CW. Current Therapy in Endocrinology and Metabolism. 6th ed. St Louis, Mo: Mosby-Yearbook; 1997. 179-87.
Pang S. Congenital adrenal hyperplasia. Endocrinol Metab Clin North Am. 1997 Dec. 26(4):853-91. [Medline].
Pang S, Shook MK. Current status of neonatal screening for congenital adrenal hyperplasia. Curr Opin Pediatr. 1997 Aug. 9(4):419-23. [Medline].
Stratakis CA, Rennert OM. Congenital adrenal hyperplasia: molecular genetics and alternative approaches to treatment. Crit Rev Clin Lab Sci. 1999 Aug. 36(4):329-63. [Medline].
Winter JS. Clinical, biochemical and molecular aspects of 17-hydroxylase deficiency. Endocr Res. 1991. 17(1-2):53-62. [Medline].
Yanase T. 17 alpha-hydroxylase/17,20-lyase defects. J Steroid Biochem Mol Biol. 1995 Jun. 53(1-6):153-7. [Medline].
Yanase T, Simpson ER, Waterman MR. 17 alpha-hydroxylase/17,20-lyase deficiency: from clinical investigation to molecular definition. Endocr Rev. 1991 Feb. 12(1):91-108. [Medline].